U.S. Markets close in 1 hr 50 mins

Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters

Ron Leuty
Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters

The South San Francisco company says its mid-stage study was one of the best for people with ALS; investors initially were skeptical.